No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

9T Labs Raises $17M Series A Funding

Editor: What To Know

  • The money raised during the Series A investment round will be used to fund the next phase of growth at 9T Labs to help its customers ramp up their applications to mass volumes, complement the current material portfolio, and develop future technology platforms.
  • “This round of investment and the combined expertise with our partners will allow us to make the next big leap in commercialization and fulfilling our mission to enable widespread replacement of metal parts with fully recyclable high-performance carbon composite materials,” adds Martin Eichenhofer, 9T Labs co-founder and CEO.
  • The global 3D printing market is predicted to grow at a compounded annual growth rate (CAGR) of 25% to exceed a value of $100-billion USD by 2030 in the $2-trillion USD global parts manufacturing segment.

9T Labs: Composite equipment and software OEM 9T Labs AG announced today that it closed its Series A funding round and raised $17-million USD to help further commercialize the company’s innovative Red Series® Additive Fusion SolutionTM platform for the production of advanced carbon fiber-reinforced thermoplastic (CFRTP) composite parts.

Key investors include the world’s leading 3D printing company Stratasys, the venture capital arm of high-performance thermoplastic composites supplier Solvay SA (Solvay Ventures), as well as VC investors Verve Ventures, ACE & Company, Zürcher Kantonalbank and Wingman Ventures.

9T Labs’ technology platform enables desktop size high-performance structural parts to be produced in CFRTP composites in production volumes ranging from 100 to over 100,000 parts/year. By combining software, 3D printing — offering unexcelled design freedom, part complexity, and control of fiber orientation — with compression molding in matched metal dies – providing rapid cycle times, high production rates, excellent surface finishes and low voids, plus high repeatability and reproducibility (R&R) — 9T Labs’ Red Series platform offers the best of both additive and existing manufacturing to create a more sustainable and high-performance alternative to traditional metal and plastic manufacturing technologies.

It is used by Fortune 500 aerospace companies to lightweight its future mobility programs, by medical corporations to reduce material waste for manufacturing medical instruments and by the leisure and luxury industry to provide consumer products with increased functionality. The global 3D printing market is predicted to grow at a compounded annual growth rate (CAGR) of 25% to exceed a value of $100-billion USD by 2030 in the $2-trillion USD global parts manufacturing segment.

9T Labs has combined the simplicity of 3D printing with the strength of continuous carbon fiber composites, and that’s an exciting development for our industry,” said Adam Pawloski, VP Manufacturing Solutions at Stratasys. “Their Additive Fusion Technology leverages the benefits of printing, automated tape laying, and compression molding to deliver fully dense parts with multidirectional reinforcement. Moreover, this technology scales to the volumes of production parts needed by serial manufacturers. The end result is a solution with the potential to dramatically shift the industry away from metal and towards composite parts.”

“As a leading supplier of thermoplastic composites technologies, we are excited to contribute our materials expertise to help accelerate 9T Labs’ developments in the 3D printing space to produce structural composite parts,” adds Fabrizio Ponte, head of Thermoplastic Composites Platform, Solvay SA.

Following the investment round, John Hartner, former Chief Executive Officer of ExOne (Pittsburgh, PA, USA) will join 9T Labs’ board of director as chairman. Hartner is an experienced leader with more than 30 years’ involvement in the automation, semiconductor, clean tech, and 3D printing industries. “I have been impressed by the company’s unique solution and am very excited to help the team to bring this technology to manufacturing companies around the world” notes Hartner.

The money raised during the Series A investment round will be used to fund the next phase of growth at 9T Labs to help its customers ramp up their applications to mass volumes, complement the current material portfolio, and develop future technology platforms. “This round of investment and the combined expertise with our partners will allow us to make the next big leap in commercialization and fulfilling our mission to enable widespread replacement of metal parts with fully recyclable high-performance carbon composite materials,” adds Martin Eichenhofer, 9T Labs co-founder and CEO.

“Through this support, we will be able to demonstrate things we could not have imagined 10 years ago.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy